June 20, 2023
Traditional psychedelic medicines work by binding to receptors that detect serotonin, antagonising the 5-HT2a receptor specifically. Ketamine, however, works by
May 17, 2023
Psilocybin therapy for treatment-resistant depression is currently in Phase III clinical trials, and may be approved by the FDA as
April 20, 2023
After a sold-out conference in 2022, PSYCH Symposium is returning to bring together leading investors, regulators, scientists and industry leaders
January 26, 2022
Psychedelic profiles ibogaine Ibogaine is a psychoactive compound found in several plants, most notably in the roots of the iboga
January 19, 2022
Psychedelic profiles Ketamine In 2021 the psychedelic healthcare market was worth US$190 million, dominated by ketamine-assisted therapy. Distinct from other
January 11, 2022
Psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression are in Phase II trials, and may be approved by the